Thyrocare revenue up 18%, PAT 47% in Q3FY26

Thyrocare Technologies Limited has announced the results for the third quarter of the financial year 2026.

Key highlights

• Revenue from operations increased 18 percent to Rs 195. 53 crore in Q3FY26 from Rs 165.92 crore in Q3FY25.
• PAT jumped 47 percent to Rs 27. 91 crore in Q3FY26 from Rs 18.94 crore in Q3FY25.
• Reported EBITDA increased 38 percent to Rs 57.64 crore in Q3FY26 from Rs 41.64 crore in Q3FY25.

Other highlights

• In the Pathology business, franchise revenuegrew by12% year-on-year, while partnership revenue, including pharmeasy busines,s recorded a robust 39% year-on-year growth
• Thyrocare processed 49.6 million tests in Q3FY26, marking a strong 22% year-on-year growth and reinforcing its leadership position in the diagnostics industry
• Achieved Six Sigma quality standards (defined as 3.4 CPMT), reducing complaints per million tests to 3.2 (down 43% YoY) with ATAT at 3.28 hours – India’s first diagnostic chain to hit this benchmark

“We are pleased to report a robust set of results for the quarter. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India, said Rahul Guha, MD & CEO, Thyrocare Technologies Ltd.
MB Bureau